Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden

References

• Melero Moreno C, Quirce S, Huerta A, et al. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. 2019;56:861–871.
   PubMed Web of Science ®Google Scholar
• Jansson S-A, Backman H, Andersson M, et al. Societal costs of severe asthma in Sweden. Eur Respir J. 2018;52:PA1157.
   Google Scholar
• Janson C, Lisspers K, Stallberg B, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018;19:168.
   PubMed Web of Science ®Google Scholar
• Lisspers K, Janson C, Larsson K, et al. Comorbidity, disease burden and mortality across age groups in a Swedish primary care asthma population: An epidemiological register study (PACEHR). Respir Med. 2018;136:15–20.
   PubMed Web of Science ®Google Scholar
• Souliotis K, Kousoulakou H, Hillas G, et al. Direct and indirect costs of asthma management in Greece: an expert panel approach. Front Public Health. 2017;5:67.
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22:470–477.
   PubMed Web of Science ®Google Scholar
• Nwaru B, Ekström M, Wiklund F, et al. Oral corticosteroids exposure in a Swedish nationwide asthma population during 2006–2016. European Respiratory Society; 2018 [cited 2018 Nov 27] Available from: https://www.ers-education.org/events/international-congress/paris-2018.aspx?idParent=213239
   Google Scholar
• Van Ganse E, Antonicelli L, Zhang Q, et al. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med. 2006;100:140–147.
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23:723–729.
   PubMed Web of Science ®Google Scholar
• Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119:405–413.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Brightling CE, Menzies-Gow A, et al.; on behalf of the British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax. 2010;65:787–794.
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. JAA. 2018;11:193–204.
   Web of Science ®Google Scholar
• Zazzali JL, Broder MS, Omachi TA, et al. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc. 2015;36:268–274.
   PubMed Web of Science ®Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19:75.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Global Initiative for Asthma; 2018 [cited 2018 Oct 31] Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/
   Google Scholar
• Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29.
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory eosinophilic asthma. Technology appraisal guidance [TA431]. National Institute for Health and Care Excellence; 2017 Jan 25 [cited 2019 Apr 11]. Available from: https://www.nice.org.uk/guidance/ta431
   Google Scholar
• Bermejo I, Stevenson M, Cooper K, et al. Mepolizumab for treating severe eosinophilic asthma: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36:131–144.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Reslizumab for treating severe eosinophilic asthma. Technology appraisal guidance [TA479]. National Institute for Health and Care Excellence; 2017 Oct 4; [cited 2019 Apr 11]. Available from: https://www.nice.org.uk/guidance/ta479
   Google Scholar
• Cooper K, Frampton G, Harris P, et al. Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36:545–553.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118:220–225.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks. Institute for Clinical and Economic Review; 2018 Dec 20 [cited 11 Apr 2019]. Available from: https://icer-review.org/wp-content/uploads/2018/04/ICER_Asthma_Final_Report_122018-1.pdf
   Google Scholar
• Tice JA, Campbell JD, Synnott PG, et al. The effectiveness and value of biologic therapies for the treatment of uncontrolled asthma. JMCP. 2019;25:510–514.
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Brazier J, Mccoll E, et al. Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices. White Rose University Consortium; 2002 May [cited 2018 Nov 19]. Available from: http://eprints.whiterose.ac.uk/10952/1/HEDS_DP_02-01.pdf
   Google Scholar
• Caminati M, Senna G, Stefanizzi G, et al.; on behalf of North East Omalizumab Network study group. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med. 2016;16:128.
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129:S34–S48.
   PubMed Web of Science ®Google Scholar
• European Central Bank. Swedish krona (SEK). Frankfurt: Euopean Central Bank; 2017 [cited 2018 Nov 20]. Available from: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-sek.en.html
   Google Scholar
• Voorham J, Xu X, Price D, et al. Health care resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74:273–283.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16:22–27.
   PubMedGoogle Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31:800–804.
   PubMed Web of Science ®Google Scholar
• Lundgren S, Lundquist L. Ändring i Tandvårds- och läkemedelsförmånsverkets allmänna råd (TLVAR 2003:2) om ekonomiska utvärderingar [Change in the General Council of the Dental and Medicines Benefit Agency (TLVAR 2003: 2) on financial evaluations]. Stockholm: Tandvårds och läkemedelsförmånsverkets; 2017 [cited 2018 Nov 27]. Swedish. Available from: https://www.tlv.se/download/18.467926b615d084471ac3230c/1510316374332/TLVAR_2017_1.pdf
   Google Scholar
• Statistics Sweden [internet]. Stockholm: Statistics Sweden; 2019 [cited 2019 Apr 3]. Available from: https://www.scb.se/en/
   Google Scholar
• Strong M, Oakley JE, Chilcott J. Managing structural uncertainty in health economic decision models: a discrepancy approach. J Royal Stat Soc. 2012;61:25–45.
   Google Scholar
• World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). World Health Organization; 2019 [cited 2019 Jun 25]. Available from: http://www.who.int/choice/en/
   Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–124.
   PubMed Web of Science ®Google Scholar
• Svensson M, Nilsson FOL, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33:1229–1236.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Benralizumab for treating severe eosinophilic asthma. National Institute for Health and Care Excellence; 2018 Jul [cited 2018 Nov 27]. Available from: https://www.nice.org.uk/guidance/gid-ta10192/documents/appraisal-consultation-document-2
   Google Scholar
• Mokoka MC, Lombard L, MacHale EM, et al. In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled clinical trial. BMJ Open. 2017;7:e015367.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51:1701126.
   PubMed Web of Science ®Google Scholar
• Bevan G, Helderman J-K, Wilsford D. Changing choices in health care: implications for equity, efficiency and cost. HEPL. 2010;5:251–267.
   Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost effectiveness of pharmacological treatments for asthma: a systematic review. Pharmacoeconomics. 2018;36:1165–1200.
   PubMed Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, et al. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36:957–971.
   PubMed Web of Science ®Google Scholar